NovaBay Pharmaceuticals, Inc. (NBY) News
Filter NBY News Items
NBY News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NBY News Highlights
- For NBY, its 30 day story count is now at 2.
- Over the past 24 days, the trend for NBY's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about NBY are MS.
Latest NBY News From Around the Web
Below are the latest news stories about NOVABAY PHARMACEUTICALS INC that investors may wish to consider to help them evaluate NBY as an investment opportunity.
NovaBay Pharmaceuticals Partners with Woo University to Educate Eyecare Professionals on the Use of Amniotic MembranesEMERYVILLE, Calif., December 06, 2023--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces its partnership with Woo University to support the education of eyecare professionals on the use of amniotic membranes. A free webinar is being held Thursday, December 7, 2023 from 5:30-6:30 pm Pacific time, and eyecare professionals can register here. In September 2023 NovaBay commercially launched its prescription amniotic membrane product Avenova® Allograft, which is intended for use as a prote |
NovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q3 2023 Earnings Call TranscriptNovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q3 2023 Earnings Call Transcript November 9, 2023 Operator: Welcome to the NovaBay Pharmaceuticals Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to Ms. Jody Cain. Please go ahead, ma’am. Jody Cain: This […] |
NovaBay Pharmaceuticals Reports Third Quarter 2023 Financial ResultsEMERYVILLE, Calif., November 09, 2023--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and nine months ended September 30, 2023 and provides a business update. |
NovaBay Pharmaceuticals to Hold Third Quarter 2023 Conference Call on November 9, 2023EMERYVILLE, Calif., November 02, 2023--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and nine months ended September 30, 2023 after market close on Thursday, November 9, 2023 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. |
NovaBay Pharmaceuticals Expands Physician Dispensed Sales Channel with New Avenova ProgramsEMERYVILLE, Calif., October 11, 2023--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces the launch of two new promotional programs for ophthalmologists and optometrists who help their patients manage the symptoms of chronic dry eye with Avenova®-branded products. Through the new Avenova Loyalty Program and Avenova Affiliate Program, top Avenova eyecare professionals will have access to s |
NovaBay Pharmaceuticals to Present at the Dawson James Small Cap Growth ConferenceEMERYVILLE, Calif., October 02, 2023--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that Justin Hall, CEO and General Counsel, will present a company overview and hold investor meetings at the 8th Annual Dawson James Small Cap Growth Conference being held Thursday, October 12, 2023 at the Wyndham Grand Harborside Hotel in Jupiter, Fla. |
Dawson James Securities Announces October Date for 8th Annual Small Cap Growth ConferenceJUPITER, Fla., Sept. 21, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Dawson James Securities, Inc. (“Dawson”), a full-service investment bank focused on emerging growth companies, today announces its 8th Annual Dawson James Small Cap Growth Conference on October 12, 2023, at the Wyndham Grand Hotel in Jupiter, FL. Dawson James’ flagship Small Cap Growth Conference brings together senior leadership from over 30 of the most innovative companies at the forefront of healthcare, technology and consu |
NovaBay Pharmaceuticals Announces Commercial Launch of Avenova® AllograftEMERYVILLE, Calif. & POMPANO BEACH, Fla., September 14, 2023--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces the commercial launch of Avenova Allograft to eyecare professionals across the U.S. through its physician-dispensed channel. This prescription product is the only optic allograft manufactured using BioStem Technologies, Inc.’s (OTC: BSEM) proprietary process and is intended for use as a protective covering during the repair of ocular surfaces. |
NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova® AllograftEMERYVILLE, Calif. & POMPANO BEACH, Fla., September 11, 2023--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and BioStem Technologies, Inc. (OTC: BSEM) announce an agreement under which NovaBay has been granted the right to commercialize BioStem Technologies’ Amniotic Tissue Allograft, which is intended for use as a protective covering during the repair of ocular surfaces. |
NovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q2 2023 Earnings Call TranscriptNovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q2 2023 Earnings Call Transcript August 12, 2023 Operator: Welcome to the NovaBay Pharmaceuticals Second Quarter 2023 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to Jody Cain. Please go ahead. Jody Cain : This is […] |